Company intelligence / Profile preview

Presidio Medical

San Mateo, California, USApresidiomedical.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Early clinical trials with more than 50 patients suffering from chronic pain showed "remarkable" results, with patients reporting greater than 90% average pain relief over a period of at least two weeks. The company plans to conduct large, long-term pivotal studies to further demonstrate durability and efficacy of its ULF neuromodulation system. The technology aims to address unmet needs in chronic nociceptive pain where conventional treatments have failed. No commercial product yet.

Therapeutic areas: Neurology
Modalities: Device (specifically neuromodulation device)Non-pharmacological therapy (neuromodulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ULF Neuromodulation System

Phase 1

Indications: Chronic nociceptive pain, Post-operative pain

Partnerships

None publicly disclosed as major pharma/biotech partnerships.

Beyond the preview

Go deeper on Presidio Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presidio Medical.

Explore the full profile